Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical research trials and Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "S" Clinical Trials Conditions > Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer



Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

For Condition: Ovarian Cancer
Status: No longer recruiting
Sponsor(s): Sonus Pharmaceuticals ,
Synopsis: Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or primary peritoneal carcinoma.
Details: The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: Histologic diagnosis of ovarian cancer or primary peritoneal carcinoma Stage III or IV disease One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent Platinum resistant disease, defined as documented progression within six months of completion of first line therapy Adult (18 years of age or older) patients Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than 100,000/mm3) Serum creatinine less than 2.0 mg/dL Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of institutional normal values ECOG performance status of 0 - 2 Bidimensional measurable or clinically evaluable disease Patients who have signed an IRB / Ethics Committee approved informed consent Life expectancy at least 12 weeks Patient has fully recovered from any previous surgery (at least 4 weeks since major surgery) Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients of child bearing potential must use a medically effective form of contraception during the treatment.) Exclusion Criteria: Patients who have received any taxane-containing preparation including Taxol (paclitaxel) or Taxotere (docetaxel) Females who are pregnant or lactating Patients with peripheral neuropathy NCI-CTC grade 2 or greater Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of study entry Patients who have had an investigational agent within 4 weeks of study entry Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:  SON-8184-1061; 
Study Start Date: March 2002
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034151

Other Ovarian Cancer Studies:
1. Methods in Education for Breast Cancer Genetics

2. Acupuncture to Improve Quality of Life in Patients With Advanced Cancer

3. Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

4. Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

5. A Study to Evaluate the Safety and Effect of Pertuzumab on Cancerous Lesions in Women with Advanced, Refractory or Recurrent Ovarian Cancer

Related Studies:

Other Ovarian Cancer Clinical Trials
Other Clinical Trials
Other Clinical Trials

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Modify your Search

  Other Ovarian Cancer Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103